Tosk works to alleviate the painful, debilitating, and potentially fatal side effects of front line cancer therapies
April 29, 2018
Advances in Head and Neck Cancers
April 30, 2018

Cible’s smart drug platform overcomes platinum drug resistance

Cible is a preclinical-stage cancer drug company that solves the major problems of traditional cancer therapy through the implementation of a smart drug platform. The first lead candidate, oxaliTEX, is found to be well tolerated, tumor localizing, and overcomes platinum drug resistance in pharmacological in vitro human cancer models. These attributes have high value in multiple indications that do not respond to platinum or biologicals, such as immunotherapies.

In upcoming news, Cible is presenting at the NYC Oncology Investor Conference, occurring on May 8-9 at the office of Wilson Sonsini in New York City.  Learn more and register to attend the conference at www.nyconcologyconference.com.

Leave a Reply

Your email address will not be published. Required fields are marked *